Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin

Status Completed

Clinical Trial Summary

Treatment of cancer is often improved if two or more drugs are used in combination. In animal studies, the use of the combination of ON 01910.Na (a new, unapproved drug) and irinotecan or oxaliplatin (two approved and extensively used anti-cancer drugs) gave better results against tumor cells than the use of any of the single drugs alone. In addition, the use of the combinations did not result in an increase of side effects. This clinical trial will determine what is the highest dose of ON 01910.Na that can be given safely in combination with either irinotecan or oxaliplatin in human patients.

Clinical Trial Description

This is an open-label, 2-arm, dose-escalation combination-therapy study in which patients with advanced malignancies will be assigned by the Investigator to dosing with either irinotecan plus ON 01910.Na (Group A), or oxaliplatin plus ON 01910.Na (Group B). The Investigator will make this assignment using clinical judgment, taking into consideration the patient's tumor type, UGT1A1 genotype when applicable (i.e., patients considered for treatment in Group A will be tested for UGT1A1 genotype, if not already known, and patients homozygous for the UGT1A1*28 allele will be excluded from Group A), prior treatment, and current clinical condition. Patients will be enrolled in 1 of 8 Cohorts (4 sequential Cohorts in Group A and 4 in Group B) of 3 patients each. Up to 6 additional patients will be tested at the MTD. Groups A and B will enroll and proceed simultaneously. ;

Study Design

Related Conditions & MeSH terms

Advanced Solid Tumors

Clinical Trial Details

NCT number	NCT00861328
Study type	Interventional
Source	Onconova Therapeutics, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	February 2008
Completion date	July 2011

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04972981` - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors	Phase 1
Completed	`NCT05086822` - A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors	Phase 1
Completed	`NCT03260322` - A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Phase 1
Completed	`NCT02526017` - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers	Phase 1
Recruiting	`NCT06040541` - Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors	Phase 1
Recruiting	`NCT05862831` - Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT03641794` - Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers	Phase 1
Terminated	`NCT03665129` - IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors	Phase 1
Not yet recruiting	`NCT06413680` - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies	Phase 1/Phase 2
Recruiting	`NCT05914116` - A Study of DB-1311 in Advanced/Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT01693562` - A Phase 1/2 Study to Evaluate MEDI4736	Phase 1/Phase 2
Recruiting	`NCT04387916` - A Study of KC1036 in Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT04095273` - Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug	Phase 1
Not yet recruiting	`NCT03692520` - Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT02997176` - An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)	Phase 1
Recruiting	`NCT04446260` - A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors	Phase 1
Recruiting	`NCT06239155` - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors	Phase 1/Phase 2
Terminated	`NCT02253992` - An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma	Phase 1/Phase 2
Recruiting	`NCT06076291` - An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors	Phase 1
Completed	`NCT03545971` - A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.	Phase 1